The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of baseline geriatric and quality of life assessments on treatment outcomes in ECOG-ACRIN EA2186 (GIANT): A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer.
 
Efrat Dotan
Consulting or Advisory Role - Agenus; Amgen; Ipsen; Merck; Merus NV; Olympus
Research Funding - Dragonfly Therapeutics (Inst); Gilead Sciences (Inst); Ipsen (Inst); Kinnate Biopharma (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lutris (Inst); NGM Biopharmaceuticals (Inst); Relay Therapeutics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Olympus
 
Paul Catalano
Research Funding - Astellas Pharma (Inst); Regeneron (Inst)
 
Leon Lenchik
No Relationships to Disclose
 
Robert Boutin
Research Funding - GE Healthcare
 
Xin Yao
Employment - Cleveland clinic Martin North (I)
Honoraria - OMNI; Research to Practice; Targeted Oncology
 
James Ohr
No Relationships to Disclose
 
Kian-Huat Lim
Honoraria - CURIS
Patents, Royalties, Other Intellectual Property - Hold patent for targeting MK2 as a therapeutic strategy in pancreatic cancer.
 
George Fisher
Honoraria - echina health
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Hutchison MediPharma
Research Funding - Genentech/Roche (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb Foundation
 
Namrata Vijayvergia
Honoraria - Guidepoint Global
Consulting or Advisory Role - Exelixis; RayzeBio; Taiho Oncology
Research Funding - Bristol-Myers Squibb/Medarex (Inst); ITM Isotope Technologies Munich (Inst); Oryzon Genomics (Inst); Puma Biotechnology (Inst); Zymeworks (Inst)
 
Sreenivasa Chandana
Speakers' Bureau - Natera
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Cardiff Oncology (Inst); Dicephera Pharmaceuticals, Inc. (Inst); Elevation Oncology (Inst); Exact Sciences (Inst); Genentech/Roche (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novocure (Inst); Pfizer (Inst); Qualigen Therapeutics (Inst); Zymeworks (Inst)
 
Aparna Kalyan
Honoraria - Samumed
Consulting or Advisory Role - AstraZeneca; Boston Scientific; BTG; Elevar Therapeutics; Exelixis; Genentech; Incyte
Speakers' Bureau - AstraZeneca; Boston Scientific; Exelixis; Genentech/Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
 
Richard Dunne
Consulting or Advisory Role - Exelixis; Helsinn Therapeutics; Merck; Toray Industries Inc.
 
David Zhen
Consulting or Advisory Role - Boehringer Ingelheim; Bristol Myers Squibb; Exelixis; Jazz Pharmaceuticals; Legend Biotech; Medigene
Research Funding - A2 Biotherapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Cornerstone Pharmaceuticals (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Genentech (Inst); Legend Biotech (Inst); Lilly (Inst); Medigene (Inst); Merck (Inst); Pfizer (Inst)
 
Daneng Li
Consulting or Advisory Role - Abbvie; AstraZeneca; Coherus Biosciences; Eisai; Exelixis; Genentech; Jazz Pharmaceuticals; Merck; Sumitomo Pharma Oncology; TransThera Biosciences; TriSalus Life Sciences
Speakers' Bureau - Ipsen
Research Funding - AstraZeneca (Inst)
 
Kim Reiss
Honoraria - MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Carisma Therapeutics; Foundation Medicine; Guardant Health; Merus NV; MOMA Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology; GlaxoSmithKline (Inst); Lilly (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from invention (I)
Expert Testimony - Elmhurst Hospital; NYU School of Medicine
 
Melissa Simon
Consulting or Advisory Role - Abbott; Abbott
 
Jordan Berlin
Consulting or Advisory Role - amplia; Astellas Pharma; Bayer Health; Bexion; BioSapien; Bristol-Myers Squibb/Celgene; epsilon; insmed; ipsen; Mekanistic Therapeutics; Merck; Merck KGaA; Merus; Mirati Therapeutics
Research Funding - 23andMe (Inst); Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Bristol-Myers Squibb/Celgene (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); hibercell (Inst); I-MAB (Inst); Incendia Pharmaceuticals AB (Inst); Incyte (Inst); Lilly (Inst); ribosciences (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Totus Medicines (Inst); Tyra Biosciences (Inst); Volastra Therapeutics (Inst)
Other Relationship - AstraZeneca; Boehringer Ingelheim; novocure
 
Lynne Wagner
Consulting or Advisory Role - Celgene
Travel, Accommodations, Expenses - Celgene
 
Peter O'Dwyer
Research Funding - Amgen (Inst); Array BioPharma (Inst); BBI Healthcare (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Lilly/ImClone (Inst); Minneamrita Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); syndax (Inst); Taiho Pharmaceutical (Inst)